Lusong Luo
Beijing Biocytogen (China)(CN)BeiGene (China)(CN)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cancer Mechanisms and Therapy, Chronic Lymphocytic Leukemia Research, PI3K/AKT/mTOR signaling in cancer, Microtubule and mitosis dynamics
Most-Cited Works
- → BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition(2015)540 cited
- → Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin(2010)368 cited
- → Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase(2019)338 cited
- → Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885(2006)262 cited
- → Antitumor activity of an allosteric inhibitor of centromere-associated protein-E(2010)254 cited
- → Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor(2011)169 cited
- → Mechanism of Inhibition of Human KSP by Ispinesib(2008)124 cited
- → Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase(2007)118 cited
- → The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial(2015)111 cited
- → ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism(2007)108 cited